S1.
Primary screening | Triage strategy | Age (year) | CIN2+ (N=68) | % (95% CI) | Colposcopy per CIN2+ (N) | ||||
Sensitivity | Specificity | PPV | NPV | Youden’s index | |||||
HPV, human papillomavirus; CIN2+, cervical intraepithelial neoplasia grade 2 or worse; RLU/CO, relative light units/cutoff; HC2, Hybrid Capture 2; ASC-US+, atypical squamous cells of undetermined significance or worse; VIA, visual inspection with acetic acid; 95% CI, 95% confidence interval; PPV, positive predictive value; NPV, negative predictive value. | |||||||||
Physician-careHPV ≥1.0 RLU/CO | ASC-US+ | 30 to 44 | 32 | 82.1
(67.3–91.0) |
96.1
(94.9–97.0) |
38.6
(28.8–49.3) |
99.4
(98.9–99.7) |
78.2 | 2.6 |
45 to 54 | 23 | 79.3
(61.6–90.2) |
93.4
(91.7–94.8) |
26.7
(18.5–36.9) |
99.3
(98.6–99.7) |
72.7 | 3.7 | ||
VIA | 30 to 44 | 13 | 33.3
(20.6–49.0) |
99.0
(98.3–99.4) |
50.0
(32.1–67.9) |
98.0
(97.1–98.7) |
32.3 | 2.0 | |
45 to 54 | 8 | 27.6
(14.7–45.7) |
99.4
(98.6–99.7) |
57.1
(32.6–78.6) |
97.8
(96.7–98.6) |
27.0 | 1.8 | ||
Self-careHPV ≥1.0 RLU/CO | ASC-US+ | 30 to 44 | 29 | 74.4
(58.9–85.4) |
96.9
(95.8–97.7) |
41.4
(30.6–53.1) |
99.2
(98.6–99.6) |
71.2 | 2.4 |
45 to 54 | 16 | 55.2
(37.5–71.6) |
95.7
(94.2–96.8) |
28.1
(18.1–40.8) |
98.6
(97.6–99.2) |
50.9 | 3.6 | ||
VIA | 30 to 44 | 13 | 33.3
(20.6–49.0) |
99.0
(98.3–99.4) |
50.0
(32.1–67.9) |
98.0
(97.1–98.7) |
32.3 | 2.0 | |
45 to 54 | 5 | 17.2
(7.6–34.5) |
99.5
(99.6–100) |
50.0
(23.7–76.3) |
97.5
(96.4–98.3) |
16.7 | 2.0 | ||
Physician-HC2 ≥1.0 RLU/CO | AS-CUS+ | 30 to 44 | 37 | 94.9
(83.1–98.6) |
95.2
(93.9–96.2) |
37.0
(28.2–46.8) |
99.8
(99.4–100) |
90.1 | 2.7 |
45 to 54 | 26 | 89.7
(73.6–96.4) |
93.2
(91.4–94.6) |
28.6
(20.3–38.6) |
99.7
(99.0–99.9) |
82.9 | 3.5 | ||
VIA | 30 to 44 | 16 | 41.0
(27.1–56.6) |
98.9
(98.1–99.3) |
51.6
(34.8–68.0) |
98.3
(97.4–98.8) |
39.9 | 1.9 | |
45 to 54 | 10 | 34.5
(19.9–52.7) |
99.3
(98.5–99.6) |
58.8
(36.0–78.4) |
98.0
(97.0–98.4) |
33.8 | 1.7 |